Across TCGA pan-cancer cohorts, TMEM186 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM186 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM186 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM186 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD and CCRCC are the cancer types where TMEM186 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.438	0.881	.018	2	view →
CCRCC	OS	Median	All	1.000	0.838	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TMEM186 tumor-vs-normal RNA expression · all TMEM186 data types